Category: HCV

Access to medicines amendment of the WTO TRIPS Agreement– hype or hope?

By: Ellen ‘t Hoen, Global Health Unit Department of Health Sciences, UMCG Groningen, e.f.m.t.hoen@umcg.nl On 30 January the World Trade Organization (WTO) announced the first ever amendment to the TRIPS Agreement under the headline WTO members welcome entry into force of...

/ 5 April 2017

The HepC Pill Bill

Source : hepCoalition The HepC Pill Bill-An insight into the availability, pricing and accessibility of HCV treatment Introduction to Direct Acting Antivirals Hepatitis C treatment has remarkably evolved over the years. The previously known standard HCV regimen consisted of a...

/ 5 April 2017

Amendment of the TRIPS Agreement

WTO members on 6 December 2005 approved changes to the WTO’s intellectual property (TRIPS) agreement in order to make permanent a decision on patents and public health originally adopted in 2003. This was formally built into the TRIPS Agreement after...

/ 23 January 2017

Global Fund Notifies Countries on 2017-2019 Allocations

For the 2017-2019 allocation period, the Global Fund adopted a refined allocation methodology to deliver the aims of its 2017-2022 strategy and to increase the impact of country programs that prevent, treat and care for people affected by HIV, TB...

/ 21 December 2016

Civil Society Calls on WHO to Include Report from UN’s High Level Panel on Medicines on WHO Board Agenda

Dear Director General Dr. Margaret Chan Request to include discussion of the United Nations Secretary-General’s High Level Panel Report on Access to Medicines at the next WHO Board meeting As members of the Make Medicines Affordable campaign, and other Civil...

/ 28 February 2016

Morocco: Creation of a collective for t the right to health in the framework of the negotiations of the EU ALECA

At a time when the Kingdom of Morocco and the European Union are preparing to resume negotiations on the "comprehensive and thorough free trade agreement" (FTAA), Moroccan civil society unites to bell Alarm about ALECA's danger of access to generics...

/ 12 January 2016

Building Capacity on Intellectual Property, Free Trade Agreement and Access to Medicines Workshop

ATL MST – ITPC MENA WORKSHOP TUNISIA 16, 17 & 18 NOVEMBER 2015 One of the most pressing issues in the 21st century is the lack of availability of essential medicines to poor patients in underdeveloped and developing countries. The...

/ 20 November 2015

HCV

Hepatitis C: Hepatitis C virus (HCV), is a major health concern in MENA. A country like Egypt for example has the highest prevalence of HCV in the world. Pakistan has also a significant number of people with HCV infection. In...

/ 1 October 2015

Launch of Moroccan Generic Sofosbuvir: A Victory for the Wide-spread Use HCV Treatment in Morocco

According to the Ministry of Health, 625,000 people are infected by HCV, 1.6% of the general population of Morocco. Of those infected, 267,000 people have active chronic infection requiring treatment. Until recently, the management of HCV infection has been hampered...

/ 26 June 2015

Treatment Advocates Denounce Gilead’s Embargo against Thousands of Tunisians Suffering from HCV Infection

The Tunisian Association of Fight against STDs and AIDS (ATL Tunis) and the International Treatment Preparedness Coalition in MENA Region (ITPC-MENA) denounce the refusal of Gilead Sciences to make their drug against the Hepatitis C Virus (HCV), sofosbuvir, available to...

/ 20 May 2015